Pancreatitis
Drug research and approvals for pancreatitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 139 studies of pancreatitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, FDA has 0 approved and 5 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 139
- Trials authorized in Canada: 4
- FDA orphan approvals: 0
- EU medicines: 1
- The imPAct of nutritioN on the Outcome of pancrEATic Surgery; Food for Thought.NCT07940309 · Not reported · Maastricht University Medical Center · starts Oct 1, 2026
- A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of CBT-248 in Healthy Adult…NCT07905053 · Phase 1 · Cibus Therapeutics, Inc. · starts Oct 15, 2026
- Diagnostic Utility of Protein Biomarkers in Pancreatic Ductal AdenocarcinomaNCT07875582 · Not reported · Grigore T. Popa University of Medicine and Pharmacy · starts Oct 8, 2026
- Inebilizumab for the Treatment of Patients With Type 1 Autoimmune PancreatitisNCT07862075 · Phase 4 · Ruijin Hospital · starts Oct 1, 2025
- Management and Outcomes of Local Complications of Acute Pancreatitis and Postoperative Pancreatic FistulaNCT07862088 · Not reported · Tokyo University · starts Sep 14, 2023
- Metabolic Impact of Pancreatic Duct DecompressionNCT07810309 · Phase 1 · Mayo Clinic · starts Oct 30, 2026
- Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary…NCT07803965 · Phase 2 · Beijing Sungen Biomedical Technology Co., Ltd · starts Sep 30, 2026
- Tacrolimus as Prophylaxis of Post-ERCP PancreatitisNCT07781722 · Phase 4 · Amsterdam UMC, location VUmc · starts Oct 16, 2026
- Short-Stay Aggressive Hydration to Prevent Post-ERCP PancreatitisNCT07776561 · Not applicable · Westmead Hospital · starts Jun 1, 2026
Approved 1
Phase 3 6
- IndomethacinCyclooxygenase inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- DoripenemBacterial penicillin-binding protein inhibitor
- SomatostatinSomatostatin receptor agonist
- Glycerin
- Nitric acid
Phase 2 12
- KetorolacCyclooxygenase inhibitor
- SimvastatinHMG-CoA reductase inhibitor
- Zegocractin
- IbuprofenCyclooxygenase inhibitor
- ValdecoxibCyclooxygenase-2 inhibitor
- StreptokinasePlasminogen activator
- SecretinSecretin receptor agonist
- MethylnaltrexoneMu opioid receptor antagonist
- PancrelipaseFatty acids hydrolytic enzyme
- Pirfenidone
- NaldemedineMu opioid receptor antagonist
- Hemin
Phase 1 or earlier 9
- DiclofenacCyclooxygenase inhibitor
- Dabigatran etexilateThrombin inhibitor
- AprotininPlasminogen inhibitor
- AmlodipineVoltage-gated L-type calcium channel blocker
- MeropenemBacterial penicillin-binding protein inhibitor
- AcetylcysteineGlutathione precursor
- GSK-065
- TramadolMu opioid receptor agonist
- PentoxifyllineAdenosine A2 receptor antagonist
How its trials ended
721 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 137 whose ending is known, 34% met their primary endpoint, 13% missed it and 53% stopped early.
- Completed, result not reported26737%
- Ongoing17524%
- Status unknown14220%
- Met its primary endpoint477%
- Stopped: other or unclear426%
- Missed its primary endpoint182%
- Stopped: enrollment or feasibility132%
- Stopped: sponsor or business decision71%
- Stopped: lack of efficacy61%
- Stopped: safety3<1%
- Stopped: funding1<1%
| May 27, 2026 | Double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of plozasiran in adults with severe hypertriglyceridemia at high risk of…Plozasiran (ADS-005) | Arrowhead Pharmaceuticals, Inc. | Ongoing |
| Jun 4, 2025 | A phase 2a, multi-center, randomized, open-label study to evaluate the safety & efficacy of a single dose of RABI-767 admin by endoscopic ultrasound-guided…RABI-767 | Panafina, Inc. | Ongoing |
| Jun 22, 2021 | Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of evinacumab in patients with severe hypcrtriglyceridemia for the…REGN1500 | Regeneron | Closed |
| Jan 22, 2014 | Timing of indomethacin administration for the prevention of post-ercp pancreatitisIndomethacin | Governors of The University of Alberta | Pending |
| Oct 22, 2025 | Camostat mesilateTreatment of chronic pancreatitis | Pangenix Pharma Limited | Designated |
| Jul 1, 2024 | ProglumideTreatment of chronic pancreatitis | CCKr Therapeutics. Inc. | Designated |
| Sep 9, 2020 | ProglumideTreatment of Chronic Pancreatitis | RNR BioMedical Inc. | Designated |
| Sep 5, 2019 | PEGylated recombinant human tumor necrosis factor-related…Treatment of chronic pancreatitis. | Theraly Fibrosis, Inc. | Designated |
| May 18, 2011 | CamostatTreatment of chronic pancreatitis | NIXS Corporation | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| May 3, 2019 | WaylivraVolanesorsen · orphan | Akcea Therapeutics Ireland Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA